Do Not Throw In Towel On Biosimilars, Says New Sandoz Chief
Executive Summary
Assertions that the US should give up on supporting biosimilars in favor of controlling prices of off-patent biologic brands fail to recognize promising signs of progress, argues Richard Saynor, who has just taken over as CEO of biosimilars pioneer Sandoz.
You may also be interested in...
AmerisourceBergen Sees Momentum Build In US Biosimilars
AmerisourceBergen’s senior director of biosimilars, Sean McGowan, believes that momentum is continuing to build for US biosimilars in 2021, especially with key developments involving insulins and interchangeability on the horizon.
Sandoz’ Saynor Insists US Biosimilars Market Is Stepping Up
Sandoz CEO Richard Saynor says he sees promising signs from the US biosimilars market that suggest it is beginning to meet its potential, albeit remaining many years behind the European market.
Wave Of Launches Boosts US Biosimilars Market
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.